The anti‐epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA‐ and glycine‐gated currents
- 1 July 2002
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 136 (5) , 659-672
- https://doi.org/10.1038/sj.bjp.0704766
Abstract
In this studyin vitroandin vivoapproaches were combined in order to investigate if the anti‐epileptic mechanism(s) of action of levetiracetam (LEV; Keppra®) may involve modulation of inhibitory neurotransmission. GABA‐ and glycine‐gated currents were studiedin vitrousing whole‐cell patch‐clamp techniques applied on cultured cerebellar granule, hippocampal and spinal neurons. Protection against clonic convulsions was assessedin vivoin sound‐susceptible mice. The effect of LEV was compared with reference anti‐epileptic drugs (AEDs): carbamazepine, phenytoin, valproate, clonazepam, phenobarbital and ethosuximide. LEV contrasted the reference AEDs by an absence of any direct effect on glycine‐gated currents. At high concentrations, beyond therapeutic relevance, it induced a small reduction in the peak amplitude and a prolongation of the decay phase of GABA‐gated currents. A similar action on GABA‐elicited currents was observed with the reference AEDs, except ethosuximide. These minor direct effects contrasted with a potent ability of LEV (EC50=1 – 10 μM) to reverse the inhibitory effects of the negative allosteric modulators zinc and β‐carbolines on both GABAAand glycine receptor‐mediated responses. Clonazepam, phenobarbital and valproate showed a similar ability to reverse the inhibition of β‐carbolines on GABA‐gated currents. Blockade of zinc inhibition of GABA responses was observed with clonazepam and ethosuximide. Phenytoin was the only AED together with LEV that inhibited the antagonism of zinc on glycine‐gated currents and only clonazepam and phenobarbital inhibited the action of DMCM. LEV (17 mg kg−1) produced a potent suppression of sound‐induced clonic convulsions in mice. This protective effect was significantly abolished by co‐administration of the β‐carboline FG 7142, from a dose of 5 mg kg−1. In contrast, the benzodiazepine receptor antagonist flumazenil (up to 10 mg kg−1) was without any effect on the protection afforded by LEV. The results of the present study suggest that a novel ability to oppose the action of negative modulators on the two main inhibitory ionotropic receptors may be of relevance for the anti‐epileptic mechanism(s) of action of LEV. British Journal of Pharmacology(2002)136, 659–672; doi:10.1038/sj.bjp.0704766Keywords
This publication has 64 references indexed in Scilit:
- Genetic variation of the human glycine receptor subunit genesGLRA3 andGLRB and susceptibility to idiopathic generalized epilepsiesAmerican Journal of Medical Genetics, 2001
- A Nonsense Mutation in the α1 Subunit of the Inhibitory Glycine Receptor Associated with Bovine MyoclonusMolecular and Cellular Neuroscience, 2001
- Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugsPharmacological Research, 2000
- GLYCINE RECEPTORS: WHAT GETS IN AND WHY?Clinical and Experimental Pharmacology and Physiology, 1999
- Inhibition by levetiracetam of a non‐GABAA receptor‐associated epileptiform effect of bicuculline in rat hippocampusBritish Journal of Pharmacology, 1997
- Cerebellar granule cells in vitro recapitulate the in vivo pattern of GABAA-receptor subunit expressionDevelopmental Brain Research, 1995
- Amino acid-induced responses in CNS neurones of normal mouse and Wriggle Mouse SagamiNeuroReport, 1994
- Potassium-induced release of neuronotoxic activity by astrocytesBrain Research, 1987
- Limbic seizures produced by pilocarpine in rats: Behavioural, electroencephalographic and neuropathological studyBehavioural Brain Research, 1983
- Kainic acid as a tool for the study of temporal lobe epilepsyLife Sciences, 1981